Disclaimer



This presentation and the information contained herein have been prepared by and is the sole responsibility of Protector Forsikring ASA (the "Company"). Such information is being provided to you solely for your information and may not be reproduced, retransmitted, further distributed to any other person or published, in whole or in part, for any purpose. Failure to comply with this restriction may constitute a violation of applicable securities laws. The information and opinions presented herein are based on general information gathered at the time of writing and are therefore subject to change without notice. The Company assumes no obligations to update or correct any of the information set out herein.

These materials may contain statements about future events and expectations that are forward-looking statements. Any statement in these materials that is not a statement of historical fact including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations is a forward-looking statement that involves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no obligations to update the forward-looking statements contained herein to reflect actual results, changes in assumptions or changes in factors affecting these statements.

This presentation does not constitute or form part of, and is not prepared or made in connection with, an offer or invitation to sell, or any solicitation of any offer to subscribe for or purchase any securities and nothing contained herein shall form the basis of any contract or commitment whatsoever. No reliance may be placed for any purposes whatsoever on the information contained in this presentation or on its completeness, accuracy or fairness. The information in this presentation is subject to verification, completion and change. The contents of this presentation have not been independently verified. While the Company relies on information obtained from sources believed to be reliable, it does not guarantee its accuracy or completeness. Accordingly, no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its owners, directors, officers or employees or any other person as to the accuracy, completeness or fairness of the information or opinions contained in this presentation. None of the Company, its affiliates or any of their respective advisors or representatives or any other person shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. The Company's securities have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), and are offered and sold only outside the United States in accordance with an exemption from registration provided by Regulation S of the US Securities Act.

This presentation should not form the basis of any investment decision. Investors and prospective investors in securities of any issuer mentioned herein are required to make their own independent investigation and appraisal of the business and financial condition of such company and the nature of the securities. Any decision to purchase securities in the context of a proposed offering of securities, if any, should be made solely on the basis of information contained in any offering documents published in relation to such an offering. For further information about the Company, reference is made public disclosures made by the Company, such as filings made with the Oslo Stock Exchange, periodic reports and other materials available on the Company's web pages.



Q1 2020 Interim results

Investor Presentation

Oslo, 29 April 2021



Sverre Bjerkeli Chief Executive Officer





Our DNA

Vision

The Challenger

Business Idea

This will happen through unique relationships, best in class decisionmaking and cost effective solutions

Main targets

Cost and quality leadership

Profitable growth

Top 3

Values

Credible

Innovative/Open

Bold

Committed



Result highlight Q1 2021


Combined ratio at 91.1% | Investment return at 4% | EPS at NOK 7



- Net combined ratio at 91.1% (98.3% in Q1 '20)
- GWP growth at 1.8% (1.5% in local currencies)
 - Exit Workers' Compensation business Denmark and Norway, MNOK 188 (6.5 %)
- Investment return of MNOK 581, or 4%
- Profit after tax of MNOK 573 (MNOK -385) EPS at NOK 7
- Special dividend of NOK 1.67 per share
- Solvency Capital Ratio at 216% post special dividend

Volume update

Volume up 1.8%, renewal rate in the Nordics is back on a good level



- MNOK 52 (1.8%) growth (1.5% in LCY)
- Supported by price increases (8.9%)
- Exit of WC in Denmark (risk and capital reasons) and from WC Health and Welfare segments in Norway (Covid-19). MNOK 188 (6.5%)
- Strong new sales Sweden
- Small UK quarter, new sales slowing down
- Behind full year guiding
 - WC exit is history, all clients with renewal date in January
 - Volume will be on a higher level the coming quarters



in MNOK

Business unit	Q1 '21	Q1 '20	Growth
Norway	856	820	36
Sweden	895	789	106
Denmark	727	813	- 86
UK	238	192	45
Finland	164	213	- 49
Protector	2 880	2 828	52
COI	47	63	- 16
Protector incl. COI	2 927	2 891	36



Claims update

Claims ratio at 78.5%, 11% down from last year

- Net claims ratio at 78.5% (89.7%)
- Run-off gains at 0.1% (0.3%)
 - Gains on WC Norway, losses on WC Denmark
- Large losses1 at 1.9% (4.6%), 5.1%-points lower than normalized
 - Gross claims ratio 4%-points better than net claims ratio

• Ahead of full-year guiding, as Q1 seasonality-wise is normally worst.



Business unit	Q1 '21 Gross	Q1 '21 Net	Q1 '20 Gross	Q1 '20 Net
Norway	68 %	84 %	94 %	96 %
Sweden	61 %	65 %	80 %	79 %
Denmark	104 %	84 %	105 %	113 %
UK	75 %	83 %	66 %	80 %
Finland	102 %	98 %	68 %	69 %
Protector	75 %	79 %	86 %	90 %



Large losses


Gross large losses¹ of MNOK 27 (1.9%)


Gross large losses of MNOK 27, or 1.9% in Q1

Volatility must be expected

- Reinsurance will sometimes influence on net claims ratio
 - When gross large losses are high, net losses are often lower
 - When gross large losses are low, net losses are often higher
 - In Q1, net losses is 4%-points higher than gross







 $^{^{\}rm 1}$ Large losses defined as gross losses or gross absolute loss adjustments > MNOK 10

² Two very large claims capped at MNOK 100

Protector Combined Ratio





Q1 2021

	Norw	ay	Swed	en	Denm	ark	UK		Finla	nd	Protec	tor
	Q1 2021	Q1 2020										
Gross premium written	856	820	895	789	727	813	238	192	164	213	2 880	2 828
Gross premium earned	343	367	434	397	207	234	334	227	70	68	1 388	1 293
Net premium earned	305	328	373	349	180	204	254	181	62	61	1 175	1 122
Gross claims ratio	68.1 %	94.3 %	61.1 %	80.3 %	103.6 %	105.0 %	75.2 %	65.7 %	101.6 %	67.6 %	74.6 %	85.5 %
Gross cost ratio	8.9 %	7.6 %	14.7 %	12.1 %	10.4 %	5.7 %	18.5 %	12.4 %	8.2 %	3.9 %	13.2 %	9.3 %
Gross combined ratio	77.0 %	101.9 %	75.7 %	92.3 %	114.0 %	110.8 %	93.7 %	78.1 %	109.8 %	71.5 %	87.8 %	94.8 %
Net claims ratio	83.7 %	96.1 %	65.1 %	78.8 %	84.1 %	112.7 %	83.2 %	80.1 %	98.3 %	69.0 %	78.5 %	89.7 %
Net cost ratio	10.5 %	4.8 %	13.3 %	11.3 %	6.5 %	8.3 %	19.0 %	13.5 %	9.2 %	1.0 %	12.6 %	8.6 %
Net combined ratio	94.2 %	100.8 %	78.4 %	90.1 %	90.6 %	121.0 %	102.2 %	93.5 %	107.5 %	70.0 %	91.1 %	98.3 %

- Quarterly volatility on country level must be expected.
- Gross and net CR in Norway and Denmark deviate significantly due to reserve changes following the Darag-deal.
- Cost is significantly elevated in Q1 due to (i) 'long-term bonus plan' linked to share price development (3%-points), and (ii) growth stemming from UK/Sweden, where commissions are driving cost ratio upward (neutral from a competitive point of view).

Country specific comments

Very good start on the year – price increases still on the agenda





Gross vs. net CR: "Darag result effect in Q1 '21" of MNOK -53.8.

GWP effect of WC exit of MNOK 31. Underlying growth and profitability looks good.

Price increases on EB products still necessary.



Good figures. New sales stronger than anticipated and will probably continue going forward. Some price increases still necessary on Property products.



Gross vs. net CR: "Darag result effect in Q1 '21" of MNOK 53.9.

GWP effect of WC exit of MNOK 159 – now history. Renewal rate on a high level on all other products.

Price increases on Motor still necessary.



"Money sent to reinsurers". Small volume quarter and low new sales, also slowing down going forward. Covid-19 continues to influence growth negatively, but UK is gradually opening up now.



No critical mass – small figures – high volatility

Accumulated Darag effect is close to zero on company level; in line with expectations







Status vs. 2021 guiding


Profitability and solidity ahead of guiding, growth lagging behind



	Guiding 2021	Result Q1	Status
Net Combined Ratio:	90-92%	91.1%	Ahead
Return on Equity (ROE):	>20%	17.5%*	Ahead
Gross Written Premium (GWP) growth:	10% (LCY)	1.5% (LCY)	Behind
Solvency II Capital Ratio (SCR):	> 150%	216%	Very solid







Investments

Investment is core


Investment performance

Gain of MNOK 581 (4.0%)

- Equity portfolio returning 27.2%, ex. put options

Q1 return on investment portfolio at 4.0%, or MNOK 581

• Bond portfolio has gained 0.7%



PROTECTOR

insurance

• Remember that we invest for the long run; quarterly gains or losses will to a great extent be unrealized.

Bond portfolio statistics

0.7% return in Q1, running yield at 2.0% before cost of risk


- Bond portfolio returning 0.7%, or MNOK 92
 - Significant administrative cost effect in Q1 due to long term bonus agreements
- Running yield at 2.0%, before cost of risk
 - Avg. spread down 31 bps and avg. ref. rate down 8 bps relative to YE2020
- HY portfolio totalling BNOK 4.2
 - HY fund investments totalling MNOK 1.4bn
- Very strong Nordic HY market in Q121
 - DNB Markets Nordic HY index yielding +3.6%
- One very positive outcome on a high-risk position in quarter



Portfolio data	31.03.21	31.12.20	31.03.20
Size bond & cash eq. (MNOK) ¹	12 472	11 603	10 151
Avg. ref. rate (NIBOR, STIBOR, etc.)	0.1%	0.2%	0.5%
Avg. spread/risk premium (bps)	179	210	320
Yield	2.0%	2.3%	2.1%
Duration	0.4	0.4	0.4
Credit duration ²	1.4	1.4	2.2
Avg. rating ³	A-	A-	Α

¹ Size excludes forward foreign currency contracts

³ Avg. based on official rating (>60%) and 'Protector rating' (<40%) & is based on linear rating (as usual). WARF methodology would give a somewhat lower IG-rating



 $^{^1}$ Avg. based on official rating (>60%) and 'Protector rating' (<40%) & is based on linear rating (as usual). WARF methodology would give a somewhat lower IG-rating






² Avg. includes bank deposits

Equity portfolio statistics

Portfolio returning 27.2%

- Equities gaining 27.2% in Q1, or 508 MNOK
- Equity share at 16.2% (13.5% YE2020).
- Discount to estimated intrinsic value at 15%
- Currently 20 companies in the portfolio











Our DNA

Vision

The Challenger

Business Idea

This will happen through unique relationships, best in class decisionmaking and cost effective solutions

Main targets

Cost and quality leadership

Profitable growth

Top 3

Values

Credible

Innovative/Open

Bold

Committed



Profit and loss

Profit of MNOK 573 – EPS at NOK 7



NOKm	Q1 2021	Q1 2020	FY 2020
Gross premiums written	2 880.2	2 828.0	5 516.3
Gross premiums earned	1 387.9	1 293.2	5 379.6
Gross claims incurred	(1 035.2)	(1 105.8)	(4 424.6)
Earned premiums. net of reinsurance	1 175.2	1 122.3	4 613.5
Other insurance related income	2.9	4.2	19.5
Claims incurred. net of reinsurance	(922.8)	(1006.4)	(3901.4)
Sales cost	(101.5)	(71.7)	(331.3)
Administration cost	(81.8)	(48.3)	(221.3)
Commission from reinsurer	35.6	23.0	81.6
Other insurance related income/expenses	(12.8)	(0.1)	5.5
Technical result	92.0	18.8	246.6
Other income/costs	(17.2)	(16.3)	(67.0)
Net financial income	523.0	(322.8)	865.2
Profit before tax	597.8	(320.3)	1 044.8
Tax	(71.0)	39.7	(160.0)
Discontinued operations	50.6	(114.7)	94.3
Net comprehensive income	(4.7)	10.4	2.4
Profit for the period	572.8	(384.9)	981.6
Claims ratio. net of reinsurance	78.5 %	89.7 %	84.6 %
Expense ratio. net of reinsurance	12.6 %	8.6 %	10.2 %
Combined ratio. net of reinsurance	91.1 %	y 98.3 %	94.8 %
Gross claims ratio	74.6 %	85.5 %	82.2 %
Gross expense ratio	13.2 %	9.3 %	10.3 %
Gross combined ratio	87.8 %	94.8 %	92.5 %
Retention rate	84.7 %	86.8 %	85.8 %
Earnings per share	7.0	(4.8)	12.0

• GWP growth at 1.8% (1.5% in LCY)

• High cost due to long-term bonus plan (linked to share price development)

• 4% return on investments; 27.2% on equities and 0.7% on fixed income securities

- 3.3%-points lower than net CR; meaning money "is sent" to reinsurers
- Earnings per share at NOK 7





Balance Sheet


SCR-ratio at 216% post special dividend

In millions	31.03.2021	31.03.2020	31.12.2020
Owner-occupied property	0.0	12.7	0.0
Financial assets	13 400.5	10 337.6	11 988.6
Derivatives	73.0	300.9	47.9
Bank deposits	165.5	182.9	263.2
Other assets	4 495.1	3 480.4	2 554.9
Discontinued operations	1 876.4	2 301.9	1 895.7
Total assets	20 010.5	16 616.4	16 750.3
Total equity	3 584.5	1 630.4	3 030.5
Subordinated loan capital	1 472.9	1 243.3	1 473.0
Total reserves	10 520.2	10 662.0	9 185.1
Derivatives	59.7	150.6	61.4
Other liabilities	3 349.4	1 414.4	1 888.7
Discontinued operations	1 023.7	1 515.7	1 111.6
Total equity and liabilities	20 010.5	16 616.4	16 750.3

- Change in SCR-ratio driven by WC Darag-deal, investment result and improved technical profitability
 - Own funds are adjusted for dividend
- Downside still protected by financial options and a solvency-based reinsurance agreement



SCR-ratio composition







Solvency II




Composition of SCR:

- Net insurance risk 58%
- Net market risk 32%
- Other risks 10%

SCR composition 4 000 97 285 3 500 1 150 3 000 2 500 1 044 2 121 1 476 2 000 477 1 500 1 000 634 500 SCR Health Non-life Market Operational CD Divers. LAC

Eligible SII capital:

- Accumulated dividend subtracted from eligible capital
- Guarantee provision subtracted from own funds
- Unutilized funding will go to zero following Q2 (bond renewal)




Capital allocation – maximize shareholder return



Priority 1: Always profitable growth in insurance, if possible

Main capital allocation alternatives:



- Allocation towards profitable growth is preferred; stay disciplined
- Challenging to allocate capital in times of low credit spreads and all-time-high stock markets
- How much capital should be kept for future financial market crises?
- 4 An attractive alternative if meeting hurdle; will normally have to bid with significant premium
- Capital base discipline; flexible distribution of excess capital if allocation cannot be made elsewhere

Capital allocation approach

- Determine minimum hurdle rate (RoE>20%)
- Calculate returns for all internal and external allocation alternatives available, by return and risk
- Deploy capital in the most attractive alternatives above hurdle.
- Release underperforming capital (COI, Price increases, WC Denmark and Norway as example)








Dividend policy



Special dividend of NOK 1.67 per share – Flexible shareholder distribution policy

Solvency II ratio



- Special dividend of MNOK 137.5 (NOK 1.67 per share); to be paid out around 12 May (ex. dividend 4 May)
- Quarterly assessment going forward

Result highlight Q1 2021

Combined ratio at 91.1% | Investment return at 4% | EPS at NOK 7



- Net combined ratio at 91.1% (98.3% in Q1 '20)
- GWP growth at 1.8% (1.5% in local currencies)
 - Exit Workers' Compensation business Denmark and Norway, MNOK 188 (6.5%)
- Investment return of MNOK 581, or 4%
- Profit after tax of MNOK 573 (MNOK -385) EPS at NOK 7
- Special dividend of NOK 1.67 per share
- Solvency Capital Ratio at 216% post special dividend











Appendix

Key ratio description



Ratio

- (1)Claims ratio, net of reinsurance
- (2)Expense ratio, net of reinsurance
- (3)Combined ratio, net of reinsurance
- (4)Gross claims ratio
- (5)Gross expense ratio
- (6) Gross combined ratio
- (7) Retention rate
- (8) Earning per share

Ratio calculation

- (1)Claims incurred in % of earned premiums, net of reinsurance
- (2)Operating expenses in % of earned premiums, net of reinsurance
- (3)Net claims ratio + net expense ratio
- (4)Gross claims incurred in % of gross premiums earned
- (5)Sales and administration costs in % of gross premiums earned
- (6)Gross claims ratio + gross expense ratio
- (7) Earned premiums, net of reinsurance in % of gross earned premiums
- (8)Profit before other comprehensive income divided by weighted number of shares





